$TNGX News

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $30

Piper Sandler Downgrades Tango Therapeutics to Neutral, Raises Price Target to $24

Jefferies Downgrades Tango Therapeutics to Hold, Raises Price Target to $27

Leerink Partners Maintains Outperform on Tango Therapeutics, Raises Price Target to $55

Wedbush Maintains Outperform on Tango Therapeutics, Raises Price Target to $33

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stifel Maintains Buy on Tango Therapeutics, Raises Price Target to $40

Is Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines?

Erasca (ERAS) Climbs 390% YTD on ‘Best-in-Class’ Potential of Cancer Treatment

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Tango Therapeutics Appoints Matthew Gall CFO, Effective Immediately

Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets

Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX)

Canaccord Genuity Initiates Coverage On Tango Therapeutics with Buy Rating, Announces Price Target of $30

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge

Evaluating Tango Therapeutics (TNGX) Rich Valuation After Recent Share Price Momentum

This Stock Is Up 1,229% in Just the Past Year, But Don’t Bet Your Retirement Money on It

Tango Therapeutics’ (TNGX) Sees Cautious Analyst Optimism Following Earnings